# POLYSAN Scientific & Technological trials: 23 (2026)

ClinicalTrials.gov lists 23 trials with POLYSAN Scientific & Technological Pharmaceutical Company as lead sponsor, 3 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by POLYSAN Scientific & Technological Pharmaceutical Company: 23 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/polysan-scientific-and-technological-pharmaceutical-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 15, 2025 | NCT07066540 | Trial of the Efficacy and Safety of Use of Drug Product Reamberin® for Pathogenetic Therapy of Viral Enteric Infection in Children Aged 1-6... | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Recruiting | Viral Enteric Infection | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066540) |
| May 2, 2025 | NCT06955416 | REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 2/3 | Recruiting | Diabetic Ketoacidosis | 312 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06955416) |
| December 16, 2024 | NCT06735898 | Evaluation of the Efficacy of Permanent Course Combined Therapy With CYTOFLAVIN® Intravenous Solution and CYTOFLAVIN Tablets, at 2-3 Stages... | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Recruiting | Ischemic Stroke | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06735898) |
| July 23, 2024 | NCT06514976 | Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Unknown | Stroke, Acute, Stroke, Ischemic | 562 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06514976) |
| February 29, 2024 | NCT06286254 | Study of Safety and Efficacy of the Drug Cycloferone in Patients with Acute Respiratory Viral Infection | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | Acute Respiratory Viral Infection | 742 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06286254) |
| December 27, 2023 | NCT06183242 | Comparative Study of REMAXA®, Enteric-coated Tablets and REMAXOL®, Solution for Infusions, in Intrahepatic Cholestasis | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 2/3 | Completed | Cholestasis, Intrahepatic | 328 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06183242) |
| December 27, 2023 | NCT06183229 | Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Influenza, Acute Respiratory Infection | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06183229) |
| July 7, 2023 | NCT05935787 | Cytoflavin in the Complex Rehabilitation of Stroke Patients | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Stroke | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05935787) |
| July 3, 2023 | NCT05928286 | Remaxol® Used in the Treatment of Patients With Gallstone Disease Complicated With Obstructive Jaundice | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | Gallstone Disease, Obstructive Jaundice | 286 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05928286) |
| March 29, 2023 | NCT05789797 | Remaxol® in Patients With Drug-induced Liver Injuries During Cancer Chemotherapy | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | Cancer, Drug Induced Liver Injury | 368 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05789797) |
| February 8, 2023 | NCT05715723 | Study of Safety and Efficiency of the Drug Reamberin® in the Intensive Care of Patients With Acute Ethanol Intoxication | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | Ethanol Intoxication | 296 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05715723) |
| March 28, 2022 | NCT05297851 | Cytoflavin in Combination With Reperfusion in Stroke Patients | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | Acute Stroke | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05297851) |
| December 29, 2021 | NCT05172180 | Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19 | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | COVID-19 | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05172180) |
| December 7, 2021 | NCT05147051 | Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 2 | Completed | Metabolic Acidosis | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05147051) |
| December 2, 2020 | NCT04649203 | Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Diabetic Neuropathies | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04649203) |
| November 17, 2020 | NCT04631484 | International Trial of Efficacy of Cytoflavin in Head Trauma | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Head Trauma,Closed | 166 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04631484) |
| December 11, 2019 | NCT04194229 | Cytoflavin in the Rehabilitation of Post-intensive Care Syndrome in Stroke Survivors | POLYSAN Scientific & Technological Pharmaceutical Company | Observational | Completed | Ischemic Stroke, Post Intensive Care Unit Syndrome | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04194229) |
| March 4, 2019 | NCT03861416 | "Unifuzol®" in Patients With Peripheral Arterial Disease | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 2 | Completed | Peripheral Arterial Disease | 360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03861416) |
| February 21, 2019 | NCT03849664 | Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Cognitive Dysfunction | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03849664) |
| February 1, 2018 | NCT03418935 | Remaxol® in Mechanical Jaundice of Non-malignant Origin | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Jaundice, Obstructive | 342 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03418935) |
| January 30, 2018 | NCT03416062 | Remaxol® in Malignant Mechanical Jaundice | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 3 | Completed | Jaundice; Malignant | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03416062) |
| January 23, 2017 | NCT03028285 | Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 1 | Completed | Peripheral Vascular Disease | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03028285) |
| October 12, 2016 | NCT02930161 | Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome | POLYSAN Scientific & Technological Pharmaceutical Company | Phase 2 | Terminated | Non-alcoholic Fatty Liver Disease | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02930161) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 2/3 | 2 |
| Phase 3 | 7 |
| Observational | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 18 |
| Recruiting | 3 |
| Unknown | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Jaundice, Obstructive | 3 |
| Stroke | 3 |
| Ischemic Stroke | 3 |
| Cholestasis, Intrahepatic | 1 |
| Diabetic Ketoacidosis | 1 |
| Cholelithiasis | 1 |
| Head Injuries, Closed | 1 |
| Brain Concussion | 1 |
| Brain Injuries, Traumatic | 1 |
| Craniocerebral Trauma | 1 |
| Cognitive Dysfunction | 1 |
| Postoperative Cognitive Complications | 1 |
| Acidosis | 1 |
| Critical Illness | 1 |
| Influenza, Human | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
| Peripheral Vascular Diseases | 1 |
| Aneurysm | 1 |
| Diabetic Neuropathies | 1 |
| Diabetes Mellitus | 1 |
| Peripheral Nervous System Diseases | 1 |
| Peripheral Arterial Disease | 1 |
| Arterial Occlusive Diseases | 1 |
| Intermittent Claudication | 1 |
| Jaundice | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Fabric wholesalers in the United States](https://specstream.ai/data/businesses/fabric-wholesalers/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
- [Language schools in the United States](https://specstream.ai/data/businesses/language-schools/united-states)
- [Brazilian restaurants in the United States](https://specstream.ai/data/businesses/brazilian-restaurants/united-states)
- [Private equity firms in the United States](https://specstream.ai/data/businesses/private-equity-firms/united-states)
